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In May 2000, an Acromegaly Treatment Workshop was
held to develop a consensus statement reflecting the inte-
grated opinions of 68 leading neuroendocrinologists and
neurosurgeons worldwide.
Acromegaly is an insidious disorder caused by a pituitary
GH-secreting adenoma resulting in high circulating levels of
GH and IGF-I (1). Unfortunately, no single therapy is com-
prehensively successful in controlling the disease and its
protean clinical manifestations, and different treatment
modes are associated with unique adverse effects and clinical
disadvantages (2). Surgery, radiation, and medical treat-
ments are available for lowering GH and IGF-I hypersecre-
tion, controlling pituitary tumor mass effects, and improving
morbidity (3). Recent studies provide a compelling rationale
for controlling GH and IGF-I secretion as being the most
significant determinant of restoring the observed adverse
mortality to control rates (4–6). Regardless of the therapeutic
mode, the goal of treatment is to control GH levels to less
than 1 g/liter after an oral glucose load (Fig. 1), normalize
age- and gender-matched IGF-I levels, ablate or reduce tu-
mor mass and prevent its recurrence, and alleviate significant
comorbid features, especially cardiovascular, pulmonary,
and metabolic derangements (7, 8).
Achieving Disease Control
Surgery
Transsphenoidal surgery is the procedure of choice for the
initial management of acromegaly, and craniotomy is very
rarely indicated (4, 5, 9–12). Uniform biochemical and local
anatomic outcome criteria should be applied in determining
success for all acromegaly treatments. Complete microad-
enoma resection and maximal removal of locally impinging
tumor and hyperfunctioning macroadenomas are desired
anatomic outcomes. Reoperation for surgically accessible re-
sidual or recurrent tumor remnants visualized by magnetic
resonance imaging (MRI) should be considered in patients
who fail to achieve surgical remission as defined by rigorous
biochemical criteria. Somatostatin receptor ligand (SRL) pre-
treatment of patients destined for surgery may be useful in
patients with serious medical complications of acromegaly
(13), but no data are available on influencing surgical
outcomes.
Technical surgical adjuncts such as endoscopy, neuronavi-
gation, intraoperative hormone assays, and intraoperative
MRI may improve operative outcome, patient satisfaction,
and complication rates, but definitive data on the impact of
these procedures on surgical outcomes are not yet available.
Early GH assessment after surgery is useful, and oral glu-
cose tolerance testing and IGF-I assessment should be per-
formed within 2–4 months after surgery and interpreted
according to established criteria for defining disease control
(8, 14). The results of pituitary surgery are optimal when
performed in specialized centers encompassing a team ap-
proach to therapy, including expertise in endocrinology,
neurosurgery, and pathology. Individual surgical expertise
is a major determinant of surgical outcomes and may be
defined as a record of peer-reviewed publication of surgical
results encompassing both endocrine and surgical evalua-
tion and follow-up; training experience of more than 100
pituitary surgery cases, and annual surgical activity of more
than 25 cases/surgeon. Specialized pituitary pathology is
desirable, and immunostaining is mandatory for rigorous
evaluation of surgical results.
Medical
GH-secreting adenomas express somatostatin receptor
forms; the SSTR2 receptor subtype appears to be a particu-
larly important mediator for signals suppressing GH secre-
tion (15). SRLs, administered by sc or im injection, effectively
control GH axis biochemical parameters in 50–70% of pa-
tients (16–18) and provide sustained hormone suppression
and alleviation of soft tissue manifestations of acromegaly as
long as drug administration is continued (19). SRLs are rec-
ommended as the mainstay of medical therapy. Oral dopa-
Abbreviations: MRI, Magnetic resonance imaging; SRL, somatostatin
receptor ligand.
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mine agonists are only effective in about 10% of patients, and
in selected patients with coexistent hyperprolactinemia, do-
pamine agonists may be a preferable therapeutic choice,
whereas combined use of SRL and dopamine agonist therapy
may improve therapeutic efficacy (20). Long-acting depot
SRL preparations and longer acting dopaminergic agents are
preferred over the short-acting agents (21–24).
The GH receptor antagonist (25) represents a novel ap-
proach for the treatment of acromegaly, particularly in so-
matostatin analog-resistant patients (26). Although the drug
is investigational, and its long-term safety profile remains to
be established, it will be especially useful for patients with
persistently elevated IGF-I levels.
Radiotherapy
Radiotherapy administered by conventional means
(45–50 Gy total dose) is associated with relatively few ad-
verse events other than hypopituitarism. Administered in
fractionated doses not exceeding 1.75 Gy/session, radiother-
apy can be considered for nonresectable or residual pituitary
disease, medical therapy failure, and/or patient refusal of
other modalities. GH and IGF-I levels decrease slowly after
fractionated conventional radiotherapy (27, 28), and the most
rapid GH decrease occurs in the first 2 yr. Medical therapy,
usually with SRLs, is often required to bridge the latency
period before the onset of radiation effectiveness. Tumor
regrowth after radiotherapy is rarely encountered, but the
time course of tumor shrinkage is variable. Radiation therapy
choices should be carefully evaluated with an informed team
approach, including the patient, endocrinologist, experi-
enced radiation oncologist, and neurosurgeon.
Several forms of radiation therapy are available, including
use of the linear accelerator, gamma knife and proton beam,
and their efficacy has been enhanced by the availability of
stereotactic techniques achieved by computerized imaging
and stereotactic technologies to maximize targeting, mini-
mize radiation field scatter, reduce treatment times, and
shorten latency to onset of effects (29–31). Most available
data rely on therapy administered a decade or more ago,
when criteria for control were not well established, and older
technologies were in use. Therefore, it is anticipated that data
will become available to ascertain whether advantages pro-
vided by the stereotactic approach achieve or improve effi-
cacy and safety. Overall, radiotherapy modalities are viewed
as adjunctive therapies to primary surgical and medical inter-
ventions (29–31).
FIG. 1. Control implies GH less than 1 ng/ml after
an oral glucose load and normalized age- and
gender-matched IGF-I levels. DXRT, Radiation
therapy.
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Control of Mass Effects
The expanding pituitary mass may impinge on vital cen-
tral structures, and alleviation of these effects is an important
goal of disease management. Improved standardization for
tumor volume assessment is recommended, including the
use of three-dimensional tumor analysis and accurate mea-
surement of tumor diameter and distance from critical struc-
tures (32). Surgery is immediately effective in debulking
tumor mass, and particularly relieves pressure on visual
tracts and improves headache. Pretreatment with SRLs may
be helpful in shrinking tumor size and potentially improving
surgical outcomes, but controlled prospective data are re-
quired (13). Tumor shrinkage is rarely observed with dopa-
mine agonists, but occurs with SRLs in approximately 50%
of patients who experience a moderate (50%) decrease in
volume, with dramatic shrinkage only in sporadic cases.
Shrinkage usually occurs within 3 months of initiating ther-
apy, but some changes are seen even after 1 yr. Doses may
be decreased with time, and no evidence of tumor regrowth
is apparent if drug treatment is maintained (17). The prob-
ability of tumor regrowth occurring if drug treatment is
discontinued should be considered, however. Radiotherapy
often produces tumor shrinkage, but the very slow onset of
action usually requires many years to be manifest. Focused
radiotherapy is probably at least as effective as standard
techniques and is possibly more rapid in onset, but more data
are required.
Relative benefits of treatments for determining disease
complications and mortality
Reductions in GH and IGF-I levels are valuable and ac-
curate markers for improvement of the comorbidity associ-
ated with acromegaly. Successful surgical adenoma resection
significantly and promptly results in mass reduction. Sur-
gery is also of value in debulking selected invasive or large
tumors even if they are not completely resectable. Medical
therapy may be offered to patients before surgery in an
attempt to reduce tumor bulk and lower GH levels, with a
comprehensive discussion outlining potential risks vs. ben-
efits of each treatment approach. Clinical judgment should
be used as to whether medical therapy should be continued
or surgical intervention recommended after evaluation of
initial responses to primary SRL treatment. It is recom-
mended that GH and IGF-I assessment be undertaken 2–3
months after medical therapy to establish dose adequacy.
Medical therapy has the advantage of not inducing hypo-
pituitarism, and selective long-term sustained GH suppres-
sion portends a favorable mortality outcome. However, the
potential benefits of preoperative medical therapy in en-
hancing surgical outcomes are as yet unknown. MRIs should
be performed within 6–9 months after surgery, and after
initiating medical treatment, MRI should be performed after
biochemical parameters have been stabilized.
Comorbidities of acromegaly should be evaluated and
treated during and after specific therapy within the clinical
context. Aggressive management of cardiovascular disor-
ders, especially hypertension, arrhythmias, and cardiac fail-
ure, should be ongoing. Sleep studies should be undertaken
in patients with documented respiratory disorders. In pa-
tients with sleep apnea, respiratory function should be mon-
itored during and after therapy initiation. Colonoscopy
should be performed every 3–5 yr depending upon clinical
indications, including family history and previous polyp
detection. The presence of other serious comorbidities
should be diagnosed and aggressively treated, especially
diabetes, arthritis, renal disease, and mandibular dysfunction.
Limitations of Treatment Modes
Surgery
In experienced hands, surgery is not life-threatening, and
cumulative major complications, including mortality, visual
impairment, and meningitis, occur in less than 2% of pa-
tients. Cerebrospinal fluid leak, permanent anterior lobe def-
icits, diabetes insipidus, and local nasal complications occur
in approximately 5% of patients. In inexperienced surgical
hands, 3- to 4-fold higher complication rates are encountered
(32, 33). Relative contraindications to surgery include patient
frailty and physical illness, and comorbidity of acromegaly.
Medical pretreatment can be offered to patients with car-
diomyopathy, cerebrovascular disease, and/or airway ob-
struction before undertaking surgery.
Medical
When initiating dopamine agonist therapy, patients
should be instructed to start with low, albeit less efficacious,
doses of dopamine agonists, because of gastrointestinal side-
effects. SRLs are associated with transient gastrointestinal
disturbances and the development of asymptomatic gall-
stones of limited clinical significance primarily during the
first 2 yr of therapy. Ultrasound evaluation before treatment
initiation is not routinely recommended. However, a com-
mitment to open-ended, long-term SRL therapy is required.
Limitations of medical treatment include severe drug intol-
erance and ongoing drug cost. To date, no serious side-effects
of SRLs or dopamine agonists have been encountered that
would limit their use (24).
Radiotherapy
In more than 60% of patients, hypopituitarism develops
within 5–10 yr. Rarely encountered, but serious, complica-
tions occur, including optic neuropathy, temporal lobe ra-
diation injury, and secondary extrapituitary neoplasms, es-
pecially in patients with cerebrovascular or organic brain
disease (34, 35). The potential neuropsychological effects of
radiation and incidence of secondary tumor development
require further study. Disadvantages of radiation include the
slow rate of GH attenuation (36) and the potential for optic
nerve damage when the adenoma is contiguous with optic
tracts.
Summary
Treatment of acromegaly is determined by the availability
of local neuroendocrine, imaging, and surgical expertise as
well as patient access to costly evaluations and therapeutic
choices, which may be unique for regions and countries.
Nevertheless, controlled GH suppression should be opti-
mized (37). In deciding on appropriate means to achieve
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biochemical control and relieve mass effects, the treating
physician team should balance risk and benefits, and treat-
ment contraindications and side-effects for each patient (2,
38). Factors to be considered include disease severity, tumor
mass effect on central structures, tumor expression of soma-
tostatin receptor subtypes, and potential for long-term pitu-
itary damage, especially in younger reproductive-aged pa-
tients. In patients who have low GH levels and already have
irreversible hypopituitarism, radiation therapy may be pre-
ferred because there is no further risk for this complication,
although tumor resection often relieves compressive hypo-
pituitarism.
The depicted flowsheet recommends surgery as the first
line therapy followed by medical therapy should surgery not
be curative. In selected patients with unacceptable anesthetic
risk, cardiovascular or pulmonary complications, and mac-
roadenomas not impinging on the optic chiasm, primary SRL
therapy may be offered (13, 39). If control is inadequately
achieved with maximal doses of SRLs and added dopamine
agonists, radiotherapy should be considered or no further
action should be proposed, depending on clinical disease
activity and degree of biochemical disease persistence. Re-
operation or treatment with investigational GH receptor an-
tagonists (25) should be considered for patients resistant to
surgical, medical, and radiotherapeutic approaches (26).
In conclusion, considering the potentially serious treat-
ment adverse effects that limit their efficacy, there is con-
sensus that integrated treatment decisions should be made
by a team including endocrinologists, surgeons, and radia-
tion therapists. The patient’s choice of therapy should be
based upon an informed understanding of the potential dis-
advantages of therapeutic approaches vs. their effectiveness
in managing this complex metabolic disorder, reducing its
comorbidities, and ultimately achieving favorable mortality
outcomes.
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